Publications by authors named "Edyta Subocz"

Claim this Profile
V
Venetoclax and obinutuzumab in first-line treatment of unfit patients with CLL - real-life data analysis of the Polish Adult leukemia group.
Klaudia Zielonka, Błażej Izdebski, Joanna Drozd-Sokołowska, Katarzyna Pruszczyk-Matusiak, Bartosz Puła, Edyta Subocz

Leuk Lymphoma· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
No advantage of antimicrobial prophylaxis in AML/MDS/CMML patients treated with azacitidine-a prospective multicenter study by the Polish Adult Leukemia Group.
Krzysztof Mądry, Karol Lis, Elzbieta Sienkiewicz, Joanna Drozd-Sokołowska, Przemysław Biecek, Edyta Subocz

Front Oncol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of novel genetic loci for risk of multiple myeloma by functional annotation.
Angelica Macauda, Klara Briem, Alyssa Clay-Gilmour, Wendy Cozen, Asta Försti, Edyta Subocz

Leukemia· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Real-World Evidence on the Fragility and Its Impact on the Choice of Treatment Regimen in Newly Diagnosed Patients with Multiple Myeloma over 75 Years of Age.
Agata Tyczyńska, Marcela Krzysława Krzempek, Alexander Jorge Cortez, Artur Jurczyszyn, Katarzyna Godlewska, Edyta Subocz

Cancers (Basel)· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Polymorphisms within Autophagy-Related Genes as Susceptibility Biomarkers for Multiple Myeloma: A Meta-Analysis of Three Large Cohorts and Functional Characterization.
Esther Clavero, José Manuel Sanchez-Maldonado, Angelica Macauda, Rob Ter Horst, Belém Sampaio-Marques, Edyta Subocz

Int J Mol Sci· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to anti-SARS-CoV-2 mRNA vaccines in multiple myeloma and chronic lymphocytic leukemia patients.
Joanna Zaleska, Paulina Kwasnik, Magdalena Paziewska, Joanna Purkot, Aleksandra Szabelak, Edyta Subocz

Int J Cancer· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A pleiotropic variant in DNAJB4 is associated with multiple myeloma risk.
Marco Dicanio, Matteo Giaccherini, Alyssa Clay-Gilmour, Angelica Macauda, Juan Sainz, Edyta Subocz

Int J Cancer· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early efficacy and safety of obinutuzumab with chemotherapy in previously untreated patients with follicular lymphoma: A real-world retrospective report of the Polish Lymphoma Research Group.
Ewa Paszkiewicz-Kozik, Iwona Hus, Monika Palka, Małgorzata Dębowska, Agnieszka Końska, Edyta Subocz

Adv Clin Exp Med· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of NPM1 alternative splicing in patients with chronic lymphocytic leukemia.
Monika Szelest, Marta Masternak, Małgorzata Zając, Michał Chojnacki, Katarzyna Skórka, Edyta Subocz

PLoS One· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Does a Multiple Myeloma Polygenic Risk Score Predict Overall Survival of Patients with Myeloma?
Angelica Macauda, Alyssa Clay-Gilmour, Thomas Hielscher, Michelle A T Hildebrandt, Marcin Kruszewski, Edyta Subocz

Cancer Epidemiol Biomarkers Prev· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A polygenic risk score for multiple myeloma risk prediction.
Federico Canzian, Chiara Piredda, Angelica Macauda, Daria Zawirska, Niels Frost Andersen, Edyta Subocz

Eur J Hum Genet· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low serum albumin level deteriorates prognosis in azacitidine-treated myelodysplastic syndromes patients - results of the PALG study 'PolAZA'.
Krzysztof Mądry, Karol Lis, Andrzej Tukiendorf, Paweł Szwedyk, Katarzyna Kapelko-Słowik, Edyta Subocz

Hematology· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bendamustine-Based Regimens as Salvage Therapy in Refractory/Relapsed Multiple Myeloma Patients: A Retrospective Real-Life Analysis by the Polish Myeloma Group.
Norbert Grzasko, Grzegorz Charlinski, Marta Morawska, Pawel Kicinski, Anna Waszczuk-Gajda, Edyta Subocz

J Clin Med· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Primary cutaneous indolent B-cell lymphomas - a retrospective multicenter analysis and a review of literature.
Magdalena Olszewska-Szopa, Marta Sobas, Kamel Laribi, Laura Bao Perez, Joanna Drozd-Sokołowska, Edyta Subocz

Acta Oncol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High efficacy of BGD (bendamustine, gemcitabine, and dexamethasone) in relapsed/refractory Hodgkin Lymphoma.
Ryszard Swoboda, Sebastian Giebel, Wanda Knopińska-Posłuszny, Ewa Chmielowska, Joanna Drozd-Sokołowska, Edyta Subocz

Ann Hematol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expression quantitative trait loci of genes predicting outcome are associated with survival of multiple myeloma patients.
Angelica Macauda, Chiara Piredda, Alyssa I Clay-Gilmour, Juan Sainz, Gabriele Buda, Edyta Subocz

Int J Cancer· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: High efficacy of BGD (bendamustine, gemcitabine, and dexamethasone) in relapsed/refractory Hodgkin lymphoma.
Ryszard Swoboda, Sebastian Giebel, Wanda Knopińska-Posłuszny, Ewa Chmielowska, Joanna Drozd-Sokołowska, Edyta Subocz

Ann Hematol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Predominant Prognostic Significance of Mutation Defined by Emulsion PCR in Chronic Lymphocytic Leukemia.
Katarzyna Skórka, Michał Chojnacki, Marta Masternak, Agnieszka Karczmarczyk, Edyta Subocz

Cancer Manag Res· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Common gene variants within 3'-untranslated regions as modulators of multiple myeloma risk and survival.
Ombretta Melaiu, Angelica Macauda, Juan Sainz, Diego Calvetti, Maria Sole Facioni, Edyta Subocz

Int J Cancer· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetically determined telomere length and multiple myeloma risk and outcome.
Matteo Giaccherini, Angelica Macauda, Enrico Orciuolo, Marcin Rymko, Karolina Gruenpeter, Edyta Subocz

Blood Cancer J· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mean Platelet Volume Has Prognostic Value in Chronic Lymphocytic Leukemia.
Marta Masternak, Bartosz Puła, Joanna Knap, Anna Waszczuk-Gajda, Joanna Drozd-Sokołowska, Edyta Subocz

Cancer Manag Res· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of high-dose corticosteroid-based treatment for chronic lymphocytic leukemia patients with p53 abnormalities in the era of B-cell receptor inhibitors.
Bartosz Puła, Monika Długosz-Danecka, Aleksander Salomon-Perzyński, Agnieszka Szymczyk, Edyta Subocz

Adv Med Sci· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term Efficacy of Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of the Polish Adult Leukemia Study Group Observational Study.
Bartosz Pula, Elzbieta Iskierka-Jazdzewska, Monika Dlugosz-Danecka, Agnieszka Szymczyk, Marek Hus, Edyta Subocz

Anticancer Res· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cereblon () gene polymorphisms predict clinical response and progression-free survival in relapsed/refractory multiple myeloma patients treated with lenalidomide: a pharmacogenetic study from the IMMEnSE consortium.
Elżbieta Iskierka-Jażdżewska, Federico Canzian, Anna Stępień, Alessandro Martino, Daniele Campa, Edyta Subocz

Leuk Lymphoma· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hodgkin lymphoma transformation of chronic lymphocytic leukemia-A real life data from the Polish Lymphoma Research Group.
Joanna Drozd-Sokołowska, Jan Maciej Zaucha, Tomasz Żółtak, Krzysztof Jamroziak, Olga Grzybowska-Izydorczyk, Edyta Subocz

Hematol Oncol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis